Omalizumab in Reducing Exacerbation Rate and Oral Corticosteroid Burden in Allergic Bronchopulmonary Aspergillosis: A Systematic Review and Meta-Analysis
Sriwijaya Journal of Internal Medicine · 25.05.2026 · 4 (1) · 16-29
DOI: 10.59345/sjim.v4i1.264 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Sriwijaya Journal of Internal Medicine, online erschienen am 25.05.2026. Verfasst von Harry Yuseptian und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction
Allergic bronchopulmonary aspergillosis (ABPA) is a hypersensitivity disorder complicating severe asthma and cystic fibrosis. Systemic corticosteroids, the mainstay of treatment, carry substantial cumulative toxicity, and the steroid-sparing role of the anti-immunoglobulin E (IgE) antibody omalizumab remained incompletely defined, particularly in South-East Asia where ABPA is under-recognised. We aimed to synthesise the most recent evidence on omalizumab in reducing exacerbations and oral corticosteroid (OCS) burden in adults with ABPA.
Methods
Following the PRISMA 2020 statement, six databases were searched for original studies enrolling at least ten ABPA patients treated with omalizumab. Standardised mean differences (Hedges' g) were pooled using a DerSimonian-Laird random-effects model with the Hartung-Knapp-Sidik-Jonkman correction. Risk of bias, subgroup, sensitivity and meta-regression analyses, and the GRADE certainty of evidence were assessed.
Results
Ten studies (n = 286) were qualitatively synthesised; eight (n = 241) entered the quantitative pool. Omalizumab produced a moderate-to-large favourable composite effect (Hedges' g = -0.69; 95% CI -1.12 to -0.25; p = 0.007). Outcome-specific pooling confirmed reduced exacerbations (g = -0.74), reduced OCS dose (g = -0.81), and improved FEV1 (g = +0.48) and asthma control (g = +0.69), corresponding to approximately 1.9 fewer exacerbations per year and 9 mg/day prednisolone equivalent. Heterogeneity was substantial (I-squared = 78.4%) but the effect was robust across leave-one-out and sensitivity analyses.
Conclusion
Omalizumab confers a clinically meaningful steroid-sparing benefit in adults with ABPA, supporting its adoption as maintenance therapy, pending adequately powered randomised trials in South-East Asian populations.
Zitieren
APA
Yuseptian, H., Fauzar, & Kurniati, R. (2026). Omalizumab in Reducing Exacerbation Rate and Oral Corticosteroid Burden in Allergic Bronchopulmonary Aspergillosis: A Systematic Review and Meta-Analysis. Sriwijaya Journal of Internal Medicine, 4(1), 16-29. https://doi.org/10.59345/sjim.v4i1.264
Vancouver
Yuseptian H, Fauzar, Kurniati R. Omalizumab in Reducing Exacerbation Rate and Oral Corticosteroid Burden in Allergic Bronchopulmonary Aspergillosis: A Systematic Review and Meta-Analysis. Sriwijaya Journal of Internal Medicine. 2026;4(1):16-29. doi:10.59345/sjim.v4i1.264
BibTeX
@article{Yuseptian2026,
author = {Yuseptian, Harry and Fauzar and Kurniati, Roza},
title = {Omalizumab in Reducing Exacerbation Rate and Oral Corticosteroid Burden in Allergic Bronchopulmonary Aspergillosis: A Systematic Review and Meta-Analysis},
journal = {Sriwijaya Journal of Internal Medicine},
year = {2026},
volume = {4},
number = {1},
pages = {16--29},
doi = {10.59345/sjim.v4i1.264}
}
EUVIMED